Benjamin K. Eschle

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

Andrei V. Krivtsov, Kathryn Evans, Jayant Y. Gadrey et al. · Cancer Cell · 2019 · 449 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +14

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs

William Flavahan, Yotam Drier, Sarah E. Johnstone et al. · Nature · 2019 · 260 citations

Medicine, Genetics, Molecular Genetics +10

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma

J. Bryan Iorgulescu, Prafulla C. Gokhale, Maria C. Speranza et al. · Clinical Cancer Research · 2020 · 172 citations · Full text

Medicine, Immunology, Oncology +17

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents

P.H. Hutson, Eleftheria N. Finger, Brian C. Magliaro et al. · Neuropharmacology · 2011 · 139 citations

Life Sciences, Neuroscience, Pharmacology +16

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Chevaun D. Morrison-Smith, Tatiana M. Knox, Ivona Filic et al. · Molecular Cancer Therapeutics · 2020 · 87 citations · Full text

Medicine, Oncology, Pharmacology +17